Fennec Pharmaceuticals Return on Equity

Fennec Pharmaceuticals (FENC) currently reports a ROE of -8.69%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Fennec Pharmaceuticals's ROE history and peer comparisons.

Fennec Pharmaceuticals's ROE of -8.69% is higher than the Healthcare sector average of -100.59%. That is roughly 91.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Fennec Pharmaceuticals's current -8.69% should be judged against Healthcare norms (sector average: -100.59%) and against FENC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -8.69%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Fennec Pharmaceuticals, and consider following FENC for alerts when major investors trade the stock.

Fennec Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -8.69% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FENC with unrelated industries.